Prism will be used by Healthcare Providers to enhance standard of care clinical outcomes. Prism uses an Amygdala-fMRI-guided model for processing EEG signals. Prism uses several electrodes EEG-signal to produce a real time Amygdala-derived-EFP biomarker signal to train patients in downregulating the Amygdala-derived-EFP biomarker during neurofeedback.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Our first-to-market solution, Prism for PTSD, is a promising software as a medical device for the treatment of PTSD as an adjunct to standard of care. About 250 million people worldwide live with PTSD, yet treatments are lacking and often lead to side effects that may last a lifetime. Prism for PTSD: An adjunct to standard of care therapy, was validated in a multi-center clinical trial in 5 medical centers in the USA and in Israel. While using Prism, patients learn to downregulate the amygdala-derived-EFP signal and how to control their PTSD symptoms under the supervision of a healthcare provider.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.